Agios Pharm Net Worth
Agios Pharm Net Worth Breakdown | AGIO |
Agios Pharm Net Worth Analysis
Agios Pharm's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Agios Pharm's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Agios Pharm's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Agios Pharm's net worth analysis. One common approach is to calculate Agios Pharm's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Agios Pharm's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Agios Pharm's net worth. This approach calculates the present value of Agios Pharm's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Agios Pharm's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Agios Pharm's net worth. This involves comparing Agios Pharm's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Agios Pharm's net worth relative to its peers.
Enterprise Value |
|
To determine if Agios Pharm is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Agios Pharm's net worth research are outlined below:
| Agios Pharm generated a negative expected return over the last 90 days | |
| Agios Pharm has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 26.82 M. Net Loss for the year was (352.09 M) with loss before overhead, payroll, taxes, and interest of (266.58 M). | |
| Agios Pharm currently holds about 819.31 M in cash with (296.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.95. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Agios Pharmaceuticals Outlines 2025 Milestones in 8-K Filing |
Agios Pharm uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Agios Pharm. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Agios Pharm's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Agios Pharm Target Price Consensus
Agios target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Agios Pharm's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 9 | Buy |
Most Agios analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Agios stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Agios Pharm, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAgios Pharm Target Price Projection
Agios Pharm's current and average target prices are 34.54 and 57.00, respectively. The current price of Agios Pharm is the price at which Agios Pharm is currently trading. On the other hand, Agios Pharm's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Agios Pharm Market Quote on 31st of January 2025
Target Price
Analyst Consensus On Agios Pharm Target Price
Know Agios Pharm's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Agios Pharm is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Agios Pharm backward and forwards among themselves. Agios Pharm's institutional investor refers to the entity that pools money to purchase Agios Pharm's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.4 M | Marshall Wace Asset Management Ltd | 2024-09-30 | 1.3 M | Bvf Inc | 2024-09-30 | 1.2 M | Polar Capital Holdings Plc | 2024-09-30 | 1 M | Bnp Paribas Investment Partners Sa | 2024-09-30 | 907 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 882.7 K | Fisher Asset Management, Llc | 2024-09-30 | 855.3 K | Vestal Point Capital Lp | 2024-09-30 | 760 K | Rock Springs Capital Management Lp | 2024-09-30 | 699.4 K | Farallon Capital Management, L.l.c. | 2024-09-30 | 5.7 M | Vanguard Group Inc | 2024-09-30 | 5.5 M |
Follow Agios Pharm's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.97 B.Market Cap |
|
Project Agios Pharm's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.32) | |
| Return On Capital Employed | (0.52) | (0.54) | |
| Return On Assets | (0.34) | (0.32) | |
| Return On Equity | (0.39) | (0.41) |
When accessing Agios Pharm's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Agios Pharm's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Agios Pharm's profitability and make more informed investment decisions.
Evaluate Agios Pharm's management efficiency
Agios Pharm has return on total asset (ROA) of (0.1818) % which means that it has lost $0.1818 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5366 %, meaning that it created $0.5366 on every $100 dollars invested by stockholders. Agios Pharm's management efficiency ratios could be used to measure how well Agios Pharm manages its routine affairs as well as how well it operates its assets and liabilities. As of the 31st of January 2025, Return On Tangible Assets is likely to grow to -0.32. In addition to that, Return On Capital Employed is likely to drop to -0.54. At this time, Agios Pharm's Non Current Assets Total are very stable compared to the past year. As of the 31st of January 2025, Non Currrent Assets Other is likely to grow to about 3.8 M, while Total Assets are likely to drop about 752.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 13.12 | 8.41 | |
| Tangible Book Value Per Share | 13.12 | 8.41 | |
| Enterprise Value Over EBITDA | (2.86) | (3.00) | |
| Price Book Value Ratio | 1.76 | 1.67 | |
| Enterprise Value Multiple | (2.86) | (3.00) | |
| Price Fair Value | 1.76 | 1.67 | |
| Enterprise Value | 1.1 B | 1.5 B |
The operational strategies employed by Agios Pharm management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 31.2099 | Revenue | Quarterly Revenue Growth 0.212 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Agios Pharm insiders, such as employees or executives, is commonly permitted as long as it does not rely on Agios Pharm's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Agios Pharm insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Agios Pharm Corporate Filings
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 7th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 2nd of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Agios Pharm Earnings Estimation Breakdown
The calculation of Agios Pharm's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Agios Pharm is estimated to be 2.8025 with the future projection ranging from a low of 2.62 to a high of 2.9125. Please be aware that this consensus of annual earnings estimates for Agios Pharm is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
2.62 Lowest | Expected EPS | 2.91 Highest |
Agios Pharm Earnings Projection Consensus
Suppose the current estimates of Agios Pharm's value are higher than the current market price of the Agios Pharm stock. In this case, investors may conclude that Agios Pharm is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Agios Pharm's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 9 | 73.6% | -2.42 | 2.8025 | 11.66 |
Agios Pharm Earnings per Share Projection vs Actual
Actual Earning per Share of Agios Pharm refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Agios Pharm predict the company's earnings will be in the future. The higher the earnings per share of Agios Pharm, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Agios Pharm Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Agios Pharm, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Agios Pharm should always be considered in relation to other companies to make a more educated investment decision.Agios Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Agios Pharm's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-10-31 | 2024-09-30 | 1.11 | -2.42 | -3.53 | 318 | ||
2024-08-01 | 2024-06-30 | -1.6 | -1.69 | -0.09 | 5 | ||
2024-05-02 | 2024-03-31 | -1.65 | -1.45 | 0.2 | 12 | ||
2024-02-15 | 2023-12-31 | -1.65 | -1.72 | -0.07 | 4 | ||
2023-11-02 | 2023-09-30 | -1.7 | -1.64 | 0.06 | 3 | ||
2023-08-03 | 2023-06-30 | -1.56 | -1.51 | 0.05 | 3 | ||
2023-05-04 | 2023-03-31 | -1.7 | -1.47 | 0.23 | 13 | ||
2023-02-23 | 2022-12-31 | -1.62 | 0.67 | 2.29 | 141 | ||
2022-11-03 | 2022-09-30 | -1.76 | -1.49 | 0.27 | 15 | ||
2022-08-04 | 2022-06-30 | -1.75 | -1.68 | 0.07 | 4 | ||
2022-05-05 | 2022-03-31 | -1.81 | -1.74 | 0.07 | 3 | ||
2022-02-24 | 2021-12-31 | -1.69 | -1.74 | -0.05 | 2 | ||
2021-11-03 | 2021-09-30 | -1.59 | -1.56 | 0.03 | 1 | ||
2021-07-29 | 2021-06-30 | -1.39 | -1.44 | -0.05 | 3 | ||
2021-04-29 | 2021-03-31 | -1.32 | 26.95 | 28.27 | 2141 | ||
2021-02-25 | 2020-12-31 | -1.33 | -1.41 | -0.08 | 6 | ||
2020-11-05 | 2020-09-30 | -1.38 | -1.43 | -0.05 | 3 | ||
2020-07-30 | 2020-06-30 | -1.37 | -1.31 | 0.06 | 4 | ||
2020-04-30 | 2020-03-31 | -1.67 | -0.59 | 1.08 | 64 | ||
2020-02-13 | 2019-12-31 | -1.72 | -1.6 | 0.12 | 6 | ||
2019-10-31 | 2019-09-30 | -1.8 | -1.81 | -0.01 | 0 | ||
2019-08-01 | 2019-06-30 | -1.7 | -1.87 | -0.17 | 10 | ||
2019-05-02 | 2019-03-31 | -1.75 | -1.59 | 0.16 | 9 | ||
2019-02-14 | 2018-12-31 | -1.67 | -1.58 | 0.09 | 5 | ||
2018-11-01 | 2018-09-30 | -1.62 | -1.63 | -0.01 | 0 | ||
2018-08-02 | 2018-06-30 | -1.55 | -1.19 | 0.36 | 23 | ||
2018-05-04 | 2018-03-31 | -1.63 | -1.63 | 0.0 | 0 | ||
2018-02-14 | 2017-12-31 | -1.66 | -1.81 | -0.15 | 9 | ||
2017-11-01 | 2017-09-30 | -1.79 | -1.59 | 0.2 | 11 | ||
2017-08-08 | 2017-06-30 | -1.56 | -1.78 | -0.22 | 14 | ||
2017-05-04 | 2017-03-31 | -1.71 | -1.56 | 0.15 | 8 | ||
2017-02-16 | 2016-12-31 | -1.51 | -1.34 | 0.17 | 11 | ||
2016-11-03 | 2016-09-30 | -1.52 | -1.63 | -0.11 | 7 | ||
2016-08-04 | 2016-06-30 | -0.48 | -1.47 | -0.99 | 206 | ||
2016-05-05 | 2016-03-31 | -0.79 | -0.61 | 0.18 | 22 | ||
2016-02-18 | 2015-12-31 | -0.5 | -1.08 | -0.58 | 116 | ||
2015-11-05 | 2015-09-30 | -0.88 | -1.07 | -0.19 | 21 | ||
2015-08-06 | 2015-06-30 | -0.46 | -0.85 | -0.39 | 84 | ||
2015-05-07 | 2015-03-31 | -0.92 | -0.13 | 0.79 | 85 | ||
2015-02-17 | 2014-12-31 | -0.58 | -0.76 | -0.18 | 31 | ||
2014-11-07 | 2014-09-30 | -0.52 | 0.1 | 0.62 | 119 | ||
2014-08-07 | 2014-06-30 | -0.4 | -0.54 | -0.14 | 35 | ||
2014-05-08 | 2014-03-31 | -0.37 | -0.39 | -0.02 | 5 | ||
2014-03-06 | 2013-12-31 | -0.34 | -0.4 | -0.06 | 17 | ||
2013-11-07 | 2013-09-30 | -0.29 | -0.47 | -0.18 | 62 | ||
2013-09-05 | 2013-06-30 | -0.32 | -2.8 | -2.48 | 775 |
Agios Pharm Corporate Management
| DSc FRSC | CoFounder Board | Profile | |
| Dr DACVP | Consultant | Profile | |
| Sarah MD | Chief Development | Profile | |
| James Burns | Corporate Officer | Profile | |
| Clive Patience | Chief Officer | Profile | |
| ShinSan Su | CoFounder Board | Profile | |
| Brian MBA | CEO Director | Profile |
Already Invested in Agios Pharm?
The danger of trading Agios Pharm is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Agios Pharm is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Agios Pharm. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Agios Pharm is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.66 | Revenue Per Share | Quarterly Revenue Growth 0.212 | Return On Assets | Return On Equity |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.